1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6434253AFFE94095D002589AA0037FC74
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/434253AFFE94095D002589AA0037FC74?OpenDocument
18
19OpenDocument
2018.97.14.81
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Product Launch Excellence

Document Excerpt: Case Study: How Horizon Therapeutics Created an Ophthalmic Blockbuster in a Rare Disease Autoimmune Area for Thyroid Eye Disease

DB Image

ID: MD-860


Features:

44 Info Graphics

13 Data Graphics

230+ Metrics

9 Narratives


Pages/Slides: 4


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5760 “Case Study: How Horizon Therapeutics Created an Ophthalmic Blockbuster in a Rare Disease Autoimmune Area for Thyroid Eye Disease”.

Industries Profiled:
Biotech; Pharmaceutical


Companies Profiled:
Amgen; Horizon Therapeutics

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.